C Aliberti1, M Tilli, G Benea, G Fiorentini. 1. Department of Interventional Radiology Delta Hospital, via delle Tombe 65, 47023 Lagosanto, Ferrara, Italy. camy.ali@libero.it
Abstract
PURPOSE: The purpose of the study was to evalutate the feasibility of irinotecan drug-eluting beads (DC Bead) administered as trans-arterial chemoembolization (TACE) in patients with liver metastases from colorectal cancer (CRC). PATIENTS AND METHODS: Ten patients with liver metastases from CRC were treated with TACE adopting irinotecan-eluting beads at a dose of 100 mg every 3 weeks. Computed Tomography (CT) was performed 24h before and after TACE. RESULTS: TACE with irinotecan eluting beads was found to be feasible and well-tolerated. Right upper quadrant pain (RUQP) lasting 4 days (range 2-7) was reported by all the patients. After 30 days, a reduction >50% of CEA levels and of the lesional contrast enhancement was observed in all the patients. CONCLUSION: Irinotecan drug-eluting beads administered as TACE were shown to be active and safe in patients with liver metastases from CRC.
PURPOSE: The purpose of the study was to evalutate the feasibility of irinotecan drug-eluting beads (DC Bead) administered as trans-arterial chemoembolization (TACE) in patients with liver metastases from colorectal cancer (CRC). PATIENTS AND METHODS: Ten patients with liver metastases from CRC were treated with TACE adopting irinotecan-eluting beads at a dose of 100 mg every 3 weeks. Computed Tomography (CT) was performed 24h before and after TACE. RESULTS:TACE with irinotecan eluting beads was found to be feasible and well-tolerated. Right upper quadrant pain (RUQP) lasting 4 days (range 2-7) was reported by all the patients. After 30 days, a reduction >50% of CEA levels and of the lesional contrast enhancement was observed in all the patients. CONCLUSION:Irinotecan drug-eluting beads administered as TACE were shown to be active and safe in patients with liver metastases from CRC.
Authors: A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol Journal: Br J Radiol Date: 2010-12-15 Impact factor: 3.039
Authors: Richard E J Forster; Sharon A Small; Yiqing Tang; Clare L Heaysman; Andrew W Lloyd; Wendy Macfarlane; Gary J Phillips; Milan D Antonijevic; Andrew L Lewis Journal: J Mater Sci Mater Med Date: 2010-06-19 Impact factor: 3.896
Authors: Robert Cg Martin; Ken Robbins; Dana Tomalty; Ryan O'Hara; Petar Bosnjakovic; Radek Padr; Miloslav Rocek; Frantisek Slauf; Alexander Scupchenko; Cliff Tatum Journal: World J Surg Oncol Date: 2009-11-03 Impact factor: 2.754